SCHEMBL2655615

SCHEMBL2655615

CCCN1Cc2nc3c(Br)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ HRH4 Q9H3N8 1/20 0.39
▸ ALDH1A1 P00352 6/20 0.36
▸ MAPK10 P53779 2/20 0.36
▸ GRM2 Q14416 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ TSHR P16473 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2662460 0.93 GRM2 (0.38) LMNAPARP1HTTPARP2HRH4
SCHEMBL2657499 0.91 HRH4 (0.38) HRH4ALDH1A1GRM2GAAKMT2A
SCHEMBL9684592 0.87 PARP1 (0.42) LMNAPARP1HTTPARP2HRH4
SCHEMBL2657022 0.86 LMNA (0.41) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL10395363 0.85 LMNA (0.40) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL9686764 0.84 ALDH1A1 (0.41) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL9686890 0.84 LMNA (0.40) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2655216 0.84 HRH4 (0.42) PARP1HRH4ALDH1A1GAAKDM4E
SCHEMBL2660713 0.83 HRH4 (0.42) LMNAPARP1HTTPARP2HRH4
SCHEMBL9685810 0.83 LMNA (0.39) LMNAPARP1HTTPARP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
EP-0245053-B1 HETEROCYCLIC FUSED TRICYCLIC COMPOUNDS ICI AMERICAS INC. (US) 1992-11-25 — — EP disclosed
US-5118688-A TETRAHYDROPYRIDOQUINOLONE DERIVATIVES USEFUL AS ANXIOLYTIC AGENTS ICI AMERICAS INC. (US) 1992-06-02 — — US disclosed
US-4975435-A Certain 1H-pyrrold[3,4-b]quinolin-1-one-9-amino-2,3-dihydro derivatives useful for treating anxiety ICI AMERICAS INC. (US) 1990-12-04 — — US disclosed
EP-0245053-A1 Heterocyclic fused tricyclic compounds ICI AMERICAS INC. (US) 1987-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF LMNA 1909/4885PARP1 1350/4885HTT 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback